Infections in the Hemato-Oncological Patient Introduction

References

• Hughes WT, Armstrong D, Bodey GP et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. CID 2002, 34: 730-751.
   Google Scholar
• Fortun J. Principal infections in the oncology patient: practical treatment. An Sist Sanit Navar 2004, 27, suppl 3: 17-21.
   Google Scholar
• Sadikot RT, Blackwell TS, Christman JW et al. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005; 171 (11): 1209-23.
   Google Scholar
• Donland RM, Costerton JW. Biofilms: survival mechanism of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15, 2: 167-193.
   Google Scholar
• Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent Infections. Science 1999; 248, 5418: 1318-1322.
   Google Scholar
• Fadda G, Nicoletti G, Schito GC et al. “Progetto Nazionale per la sorveglianza delle infezioni batteriche gravi in ambito comunitario e ospedaliero”. Istituto Superiore della Sanità, SIM 2004.
   Google Scholar
• Hooper JAC 2004
   Google Scholar
• Polk RE, Johnson CK, McClish D et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis. 2004; 39(4): 497-503.
   Google Scholar
• Iannini PB. Influence of fluorochinolone usage on ciprofloxacin resistance of Pseudomonas aeruginosa. 3rd International Meeting on Antimicrobial Chemotherapy in Clinical Practice. 2003; Abs.11
   Google Scholar
• Tillotson G. Impatto dei quadri di resistenza sulla corretta terapia antibiotica negli ospedali. Antimicrob Chemother Clin Pract, 2003; 2: 3-12.
   Google Scholar
• Mohr JF, Jones A, Ostrosky-Zeichner L et al. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university- affiliated teaching hospital: an 8-year-experience: 1995-2002. Int J Antimicrob Agents. 2004; 24 (4): 346-351.
   Google Scholar
• Hansen G, Ekert L, Metzler K et al. Comparison of the minimum inhibitory concentration, mutant prevention concentration and bactericidal concentration of ciprofloxacin and levofloxacin against enteric Gram-negative bacilli. Poster presented at the ICAAC 2002 congress, N. E70.
   Google Scholar
• Novelli A, Mini E, Mazzei T. Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections. Eur Respir Mon 2004; 9 (28): 229-254.
   Google Scholar
• Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2003 Jul;2(7):404-9.
   Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18: 3038-3051.
   Google Scholar
• Freifeld A, Marchigiani D, Walsh T et al. A doubleblind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999, 341, 5: 305-311.
   Google Scholar
• Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999, 341, 5: 312-318.
   Google Scholar
• Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br Med J 2003; 326(7399): 1111.
   Google Scholar
• GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with haematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med. 1991; 115(1):7-12.
   Google Scholar
• Micozzi A, Bucaneve G, Martino P et al. Levofloxacin compared to placebo for preventing infection in neutropenic cancer patients in a multicenter, double blind, randomized, controlled trial. Abstract presented at the ICAAC 2002 congress: N. L-991.
   Google Scholar
• Ehrlich P. Chemotherapeutics: Scientific principles, methods and results. Lancet. 1913; II: 445-451.
   Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
   Google Scholar
• Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142: 979-95.
   Google Scholar
• Bucaneve G, Micozzi A, Menicheti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005 8;353(10):977-87.
   Google Scholar
• Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005 Sep 8;353(10):988-98.
   Google Scholar
• Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38(4):681-7.
   Google Scholar
• Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995;20(3):557-60; discussion 561-3.
   Google Scholar
• Somolinos N, Arranz R, Del Rey MC, Jimenez ML. Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J Antimicrob Chemother. 1992;30(5):730-1.
   Google Scholar
• Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin Clin Infect Dis. 2002;34(11):1469-74.
   Google Scholar
• Lindsey R. Baden, M.D. Prophylactic Antimicrobial Agents and the Importance of Fitness. N Engl J Med. 2005 8;353(10): 353:1052-1054.
   Google Scholar
• Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol. 1998;99(4):206-11.
   Google Scholar
• Kern WV, Klose K, Jellen Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005; 24: 111-18.
   Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18: 3038-3051
   Google Scholar
• Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999 ; 341, 5: 305-311.
   Google Scholar
• Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999; 341, 5: 312-318.
   Google Scholar